These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

68 related items for PubMed ID: 21811172

  • 21. Crocus sativus L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo-controlled trial.
    Akhondzadeh S, Tahmacebi-Pour N, Noorbala AA, Amini H, Fallah-Pour H, Jamshidi AH, Khani M.
    Phytother Res; 2005 Feb; 19(2):148-51. PubMed ID: 15852492
    [Abstract] [Full Text] [Related]

  • 22. An evaluation of efficacy and safety of reboxetine in elderly patients affected by "retarded" post-stroke depression. A random, placebo-controlled study.
    Rampello L, Alvano A, Chiechio S, Raffaele R, Vecchio I, Malaguarnera M.
    Arch Gerontol Geriatr; 2005 Feb; 40(3):275-85. PubMed ID: 15814161
    [Abstract] [Full Text] [Related]

  • 23. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlreich MM.
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [Abstract] [Full Text] [Related]

  • 24. Treatment effects of antidepressants in patients with post-stroke depression: a meta-analysis.
    Chen Y, Guo JJ, Zhan S, Patel NC.
    Ann Pharmacother; 2006 Dec; 40(12):2115-22. PubMed ID: 17119102
    [Abstract] [Full Text] [Related]

  • 25. Relationship between poststroke depression and ischemic lesion location.
    Wongwandee M, Tangwongchai S, Phanthumchinda K.
    J Med Assoc Thai; 2012 Mar; 95(3):330-6. PubMed ID: 22550830
    [Abstract] [Full Text] [Related]

  • 26. Incidence and risk factors of poststroke depression in patients with acute ischemic stroke: A 1-year prospective study in Taiwan.
    Tsai CS, Wu CL, Hung TH, Chou SY, Su JA.
    Biomed J; 2016 Jun; 39(3):195-200. PubMed ID: 27621121
    [Abstract] [Full Text] [Related]

  • 27. Cytokine changes in the pathophysiology of poststroke depression.
    Su JA, Chou SY, Tsai CS, Hung TH.
    Gen Hosp Psychiatry; 2012 Jun; 34(1):35-9. PubMed ID: 22055333
    [Abstract] [Full Text] [Related]

  • 28. Double-blind placebo-controlled study of milnacipran in hospitalized patients with major depressive disorders.
    Macher JP, Sichel JP, Serre C, Von Frenckell R, Huck JC, Demarez JP.
    Neuropsychobiology; 1989 Jun; 22(2):77-82. PubMed ID: 2701744
    [Abstract] [Full Text] [Related]

  • 29. Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study.
    Choi-Kwon S, Han SW, Kwon SU, Kang DW, Choi JM, Kim JS.
    Stroke; 2006 Jan; 37(1):156-61. PubMed ID: 16306470
    [Abstract] [Full Text] [Related]

  • 30. Prevention of poststroke depression: 1 year randomised placebo controlled double blind trial of mianserin with 6 month follow up after therapy.
    Palomäki H, Kaste M, Berg A, Lönnqvist R, Lönnqvist J, Lehtihalmes M, Hares J.
    J Neurol Neurosurg Psychiatry; 1999 Apr; 66(4):490-4. PubMed ID: 10201422
    [Abstract] [Full Text] [Related]

  • 31. [Experience with ixel (milnacipran hydrochloride) use in the treatment of patients with post-stroke depression].
    Gekht AB, Sorokina IB, Bogolepova AN, Gudkova AA.
    Ter Arkh; 2003 Apr; 75(10):34-8. PubMed ID: 14669603
    [Abstract] [Full Text] [Related]

  • 32. [Wuling capsule played an assistant role in primary prevention of post-stroke depression: a clinical research].
    Zhu J, Hu CM, Guo SS, Wang F, Zhou Y, Zhang SY.
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2014 Jun; 34(6):676-9. PubMed ID: 25046948
    [Abstract] [Full Text] [Related]

  • 33. Double-blind randomized treatment of poststroke depression using nefiracetam.
    Robinson RG, Jorge RE, Clarence-Smith K.
    J Neuropsychiatry Clin Neurosci; 2008 Jun; 20(2):178-84. PubMed ID: 18451188
    [Abstract] [Full Text] [Related]

  • 34. Depression after minor stroke: prevalence and predictors.
    Altieri M, Maestrini I, Mercurio A, Troisi P, Sgarlata E, Rea V, Di Piero V, Lenzi GL.
    Eur J Neurol; 2012 Mar; 19(3):517-21. PubMed ID: 22175796
    [Abstract] [Full Text] [Related]

  • 35. Poststroke depression: a review emphasizing the role of prophylactic treatment and synergy with treatment for motor recovery.
    Flaster M, Sharma A, Rao M.
    Top Stroke Rehabil; 2013 Mar; 20(2):139-50. PubMed ID: 23611855
    [Abstract] [Full Text] [Related]

  • 36. [Clinico-economic assessment of milnacipran in the prevention of depressive episodes].
    Lafuma A, Dardennes R, Fagnani F, Pribil C, Bisserbe JC, Berdeaux G.
    Encephale; 1999 Mar; 25(5):401-7. PubMed ID: 10598302
    [Abstract] [Full Text] [Related]

  • 37. Double-blind treatment of apathy in patients with poststroke depression using nefiracetam.
    Robinson RG, Jorge RE, Clarence-Smith K, Starkstein S.
    J Neuropsychiatry Clin Neurosci; 2009 Mar; 21(2):144-51. PubMed ID: 19622685
    [Abstract] [Full Text] [Related]

  • 38. The assessment of poststroke depression.
    Salter K, Bhogal SK, Foley N, Jutai J, Teasell R.
    Top Stroke Rehabil; 2007 Mar; 14(3):1-24. PubMed ID: 17573309
    [Abstract] [Full Text] [Related]

  • 39. A one-year follow-up study into the course of depression after stroke.
    Bour A, Rasquin S, Aben I, Boreas A, Limburg M, Verhey F.
    J Nutr Health Aging; 2010 Jun; 14(6):488-93. PubMed ID: 20617294
    [Abstract] [Full Text] [Related]

  • 40. A Two-Phase Pathogenetic Model of Depression after Stroke.
    Werheid K.
    Gerontology; 2015 Jun; 62(1):33-9. PubMed ID: 26113201
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.